- Company
- Salespersons got worked up about pharmacy’s poor sales
- by Jung, Hye-Jin Mar 19, 2020 06:26am
- Pharmaceutical industry sales managers are also suffering from the economic downturn in the medical institution caused by the aftermath of COVID-19. This is due to the fact that some retail pharmacies refuse to pay monthly payments to pharmaceutical salesmen due to a decrease in prescriptions. Even at the end of February, quite a few mana
- Policy
- Antiepileptic drug Fycompa may face follow-on drugs soon
- by Lee, Tak-Sun Mar 19, 2020 06:26am
- Drugs using same substance as Eisai’s Fycompa film coated tablet, used to treat patients with partial-onset seizure, is preparing for a market release. Myung In Pharm and Whan In Pharm recently requested for negative scope confirmation on Fycompa’s crystalline form patent (to be expired on Oct. 14, 2026) to evade infringement. As the p
- Policy
- Boryung’s imported quadrivalent vaccine gets greenlit
- by Lee, Tak-Sun Mar 19, 2020 06:26am
- After receiving an approval on imported quadrivalent influenza vaccine, Boryung Biopharma now owns three manufactured or imported vaccine items. Sources predict the Korean company would choose an item to launch and its quantity based on the purchase price. On Mar. 16, Ministry of Food and Drug Safety (MFDS) granted an approval on Boryun
- Company
- Samsung Biologics, CDO for alzheimer's treatment
- by Lee, Seok-Jun Mar 19, 2020 06:26am
- Samsung Biologics announced on the 17th that it has signed a CDO(Contract Development Organization) partnership with Aprinoia, a Taiwanese company that is developing Alzheimer's treatment. Aprinoia is a Taiwanese bio-venture with specialized technology in developing medical equipment and therapeutics for the diagnosis of degenerative neur
- Policy
- MFDS “All Korean and U.S. COVID-19 test kits use RT-PCR"
- by Lee, Tak-Sun Mar 19, 2020 06:26am
- On Mar. 15, Korea’s Ministry of Food and Drug Safety (MFDS) has dismissed the news articles accusing Korea’s COVID-19 test kit is not even adequate for an emergency use, citing the U.S. Food and Drug Administration’s (FDA) review. According to earlier news reports by a number of Korean media, Rep. Mark Green has reportedly claimed dur
- Policy
- All traveler record accessible via DUR from Mar. 18
- by Lee, Hye-Kyung Mar 18, 2020 06:37am
- From 2 p.m., Mar. 18, information of all travelers entering Korea would be provided to healthcare providers via Drug Utilization Review (DUR) system and International Traveler Information System (ITS). Health Insurance Review and Assessment Service (HIRA) has been providing real-time information of travelers from China, Italy, Iran, Singapor
- Company
- Pharmaceutical industry focuses on Kyung-Hae Lee from GSK
- by Eo, Yun-Ho Mar 18, 2020 06:35am
- Personnel from executives of multinational pharmaceutical companies is on the list of proportional representative candidates for the United Future Party, attracting the attention of the industry. Kyung-Hae Lee(52) is the current vice president of BioGraphene and has been working in the Foreign Cooperation Department of GlaxoSmithKline (GSK
- Policy
- Ranexa by Menarini was approved in Korea
- by Lee, Tak-Sun Mar 18, 2020 06:35am
- 'Ranexa', a new treatment for cardiovascular disease, has approved Ranexa is a Ranolazine-based drug that was approved by the US FDA in January 2006. The MFDS approved Menarini Korea's 'Ranexa' (Ranolazine) as a new drug to treat angina. Ranexa is a drug developed by CV Therapeutics, which was acquired by Gilead, and Menarini owns domes
- Policy
- Avigan is not imported for COVID-19
- by Lee, Tak-Sun Mar 18, 2020 06:35am
- It was found that the health authorities decided not to import special cases of 'Avigan' (Favipiravir), a new H1N1 flu treatment used in Japan as a treatment for COVID-19. This is because there is not enough clinical evidence to use COVID-19 as a treatment. It is said that the KCDC did not make any special requests to the MFDS to decide on
- Company
- FDA clears Celltrion’s 2nd HIV drug manufacturing plant
- by An, Kyung-Jin Mar 18, 2020 06:34am
- On Mar. 16, Celltrion announced its HIV treatment CT-G07-manufactuing Cheongju facility has passed the U.S. Food and Drug Administration’s (FDA) on-site inspection with no violation. Prior to CT-G07’s global launch, the on-site inspection was carried out to confirm the plant’s manufacturing facility and quality control system. In Janua
